R-THROXY 150 TAB is a pharmaceutical formulation composed of Roxithromycin 150 mg, a semi-synthetic macrolide antibiotic used for the treatment of various bacterial infections. As a derivative of erythromycin, Roxithromycin exhibits broad-spectrum antibacterial activity, particularly effective against gram-positive and certain gram-negative organisms, making it a preferred agent in the treatment of upper and lower respiratory tract infections, skin and soft tissue infections, and genitourinary tract infections.

Roxithromycin acts by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, thereby preventing translocation of peptides. This bacteriostatic mechanism renders it effective in treating infections caused by Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Chlamydia trachomatis, and other sensitive organisms. It is especially useful in respiratory tract infections such as pharyngitis, tonsillitis, sinusitis, bronchitis, and atypical pneumonias, where it offers good tissue penetration and prolonged intracellular activity.

R-THROXY 150 TAB is manufactured by Bluepill Express in WHO-GMP certified facilities that adhere to stringent quality control measures and international compliance protocols. The tablet is formulated to offer optimal oral bioavailability with rapid gastrointestinal absorption and minimal gastrointestinal irritation. Its long half-life permits twice-daily dosing, improving patient compliance while maintaining effective plasma concentrations.

The product undergoes rigorous analytical testing, including content uniformity, assay, dissolution, and microbial limits, to ensure consistent batch-to-batch reliability. Suitable for domestic and export markets, R-THROXY 150 TAB is available in user-friendly packaging such as blister or strip formats with customizable private labeling, CTD dossiers, and global regulatory support for semi-regulated and regulated markets.

This formulation is generally well tolerated, with a lower incidence of gastrointestinal disturbances compared to other macrolides. Commonly reported side effects include mild nausea, abdominal discomfort, and occasional skin rash. Unlike erythromycin, Roxithromycin has minimal drug-drug interactions and negligible hepatotoxicity, making it safer in polypharmacy environments. It should, however, be used cautiously in patients with hepatic impairment or those receiving concurrent medications metabolized by the cytochrome P450 pathway.

R-THROXY 150 TAB offers a valuable therapeutic alternative to beta-lactam antibiotics in patients with penicillin allergies. It plays a vital role in community-acquired infections and is often recommended as first-line treatment in outpatient care due to its favorable pharmacokinetics and safety profile. Physicians may prescribe it for 5 to 10 days depending on the nature and severity of the infection.

Through the R-THROXY brand, Bluepill Express continues its mission to provide high-quality, cost-effective antimicrobial solutions to a global audience. The company supports clients through flexible third-party manufacturing agreements, bulk supply capabilities, custom export labeling, and technical documentation for product registration in international markets.